Mendus AB (publ)

Stockholm Stock Exchange IMMU.ST

Mendus AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 23.89 M

Mendus AB (publ) Net Cash Used Provided By Financing Activities is USD 23.89 M for the year ending December 31, 2023, a 2,953.57% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Mendus AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 782.53 K, a -94.40% change year over year.
Mendus AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 13.99 M, a 126.69% change year over year.
Mendus AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 6.17 M, a 7,569.92% change year over year.
Mendus AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 80.44 K, a -99.83% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Stockholm Stock Exchange: IMMU.ST

Mendus AB (publ)

CEO	Dr. Erik Manting Ph.D.
IPO Date	April 22, 2013
Location	Sweden
Headquarters	Västra Trädgårdsgatan 15
Employees	30
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years